Task: Answer Verification
Input (English): Question: Is efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : age a problem?
Answer: Elderly patients with advanced HCC, when treated with sorafenib, have an equivalent clinical outcome with similar toxicity rates as their younger counterparts. Age alone should not be a discriminating factor for the management of advanced HCC with sorafenib.
Output (English): no